Technologies for enhanced efficacy of DNA vaccines.
Technologies for enhanced efficacy of DNA vaccines.
复制标题
DOI：
10.1586/erv.11.188
复制
发表时间：
2012-02
影响因子：
6.2
通讯作者：
Petrovsky N
中科院分区：
文献类型：
--
作者：
Saade F;Petrovsky N
尽管经过多年的研究，人类DNA疫苗尚未实现其早期的承诺。在过去15年中，已经开发并在临床前模型中测试了多代DNA疫苗，用于传染病和癌症领域的预防和治疗应用，但在临床中失败了。因此，虽然DNA疫苗已成功获得兽医应用许可，但与传统的蛋白质疫苗相比，它们在人体中的免疫原性较差，阻碍了它们的进展。已经尝试了许多策略来提高DNA疫苗的效力，包括使用更有效的启动子和密码子优化，添加传统或遗传佐剂，电穿孔，皮内递送和各种初始增强策略。这篇综述总结了DNA疫苗技术的这些进展，并试图回答DNA疫苗何时可能最终被许可用于人类的问题。
Despite many years of research, human DNA vaccines have yet to fulfill their early promise. Over the past 15 years, multiple generations of DNA vaccines have been developed and tested in preclinical models for prophylactic and therapeutic applications in the areas of infectious disease and cancer, but have failed in the clinic. Thus, while DNA vaccines have achieved successful licensure for veterinary applications, their poor immunogenicity in humans when compared with traditional protein-based vaccines has hindered their progress. Many strategies have been attempted to improve DNA vaccine potency including use of more efficient promoters and codon optimization, addition of traditional or genetic adjuvants, electroporation, intradermal delivery and various prime–boost strategies. This review summarizes these advances in DNA vaccine technologies and attempts to answer the question of when DNA vaccines might eventually be licensed for human use.
登录
查看更多内容
影响因子：
14.9
作者：
Bauer AP;Leikam D;Krinner S;Notka F;Ludwig C;Längst G;Wagner R
通讯作者：
Wagner R
影响因子：
5.5
作者：
Chong, Siew-Yen;Egan, Michael A.;Israel, Zimra R.
通讯作者：
Israel, Zimra R.
影响因子：
5.5
作者：
Cazeaux, N;Bennasser, Y;Bahraoui, E
通讯作者：
Bahraoui, E
影响因子：
5
作者：
Babiuk, Shawn;Tsang, Cemaine;Griebel, Philip J.
通讯作者：
Griebel, Philip J.
影响因子：
5.5
作者：
Barbon, Christine M.;Baker, Lisa;Luby, Thomas M.
通讯作者：
Luby, Thomas M.